OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Study Identifier
191622-135
CT.gov Identifier
NCT02116361
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Depression
    • Study Drug
  • onabotulinumtoxinA
  • Normal Saline
    • Phase
    Phase 2
    Sex
    Female
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Moderate to severe major depressive disorder
    Exclusion Criteria:
    * Prior treatment with botulinum toxin of any serotype for any reason * Use of antidepressant medication for depression within 2 weeks of study * Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis

    Protocol Summary

    This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.

    Study Locations

    Location
    Status
    Location
    Woodland International Research Group
    Little Rock, Alaska, United States, 72211
    Status
    Not applicable
    Location
    CITrials
    Bellflower, California, United States, 90706
    Status
    Not applicable
    Location
    Radiant Research/Comprehensive Clinical Development, Inc.
    Cerritos, California, United States, 90703
    Status
    Not applicable
    Location
    Collaborative Neuroscience Network Inc.
    Garden Grove, California, United States, 92845
    Status
    Not applicable
    Location
    Behavioral Research Specialists, LLC
    Glendale, California, United States, 91206
    Status
    Not applicable
    Location
    Excell Research, Inc.
    Oceanside, California, United States, 92056
    Status
    Not applicable
    Showing {first} - {last} of {total} Results